ProCE Banner Activity

CE / CME

Community Oncology Best Practices in CAR T-Cell Therapy

Case Challenge
Multimedia
Watch this CME-certified on-demand Webcast of a CCO live meeting to hear expert insights for community practitioners on CAR T-cell therapy.

Pharmacists : 1.00 contact {hour} ({0.1} CEUs)

Physicians : maximum of 1.00 AMA PRA Category 1 {Credit}

Released: March 04, 2020

Expiration: March 03, 2021

No longer available for credit.

Share

Faculty

Michael R. Bishop

Michael R. Bishop, MD

Professor of Medicine, Director
Section of Hematology/Oncology,
Cellular Therapy Program
University of Chicago
Chicago, Illinois

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

Supported by educational grants from

Celgene

Gilead Sciences, Inc.

Kite A GILEAD Company

Target Audience

This program is intended for hematologists/oncologists, advanced practice registered nurses, nurses, pharmacists, and other healthcare professionals who treat and manage refractory and relapsed lymphomas and leukemias.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Recall the scientific principles underlying the use of CAR T-cells
  • Integrate recent developments, clinical trial findings, and indications of recently approved and emerging CAR T-cell therapies into clinical practice to enhance clinical outcomes
  • Determine best practices for timely referral and having proper channels of communication between community and academic centers to streamline the logistics of delivering therapy
  • Apply multidisciplinary interventions to identify and manage acute toxicities and ensure patient safety while receiving CAR T-cell therapy

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

Michael R. Bishop, MD

Professor of Medicine, Director
Section of Hematology/Oncology,
Cellular Therapy Program
University of Chicago
Chicago, Illinois

Michael R. Bishop, MD, has disclosed that he has received honoraria from Agios, Celgene, Gilead Sciences/Kite, OptumHealth, Pharmacyclics, and Sanofi; has served on speaker bureaus for Agios, Celgene, Gilead Sciences/Kite, Pharmacyclics, and Sanofi; and has received consulting fees from CRISPR Therapeutics, Gilead Sciences/Kite, Juno, Novartis, and OptumHealth.

Staff Disclosure

Staff

Taryn Gross, PhD

Director, Program Operations
inPractice Resources, LLC

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy Quill, PhD, has no relevant conflicts of interest to report.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Credit Designation

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008162-0000-20-2031-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 04, 2020, through March 03, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ competence and performance in applying evolving clinical evidence and expert guidance to best use CAR T-cells in the treatment of lymphomas and leukemias.